跳至主要内容
临床试验/NCT04150289
NCT04150289已完成不适用

A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)

pharmaand GmbH7 个研究点 分布在 1 个国家目标入组 248 人开始时间: 2019年11月4日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
248
试验地点
7
主要终点
Response to treatment

研究概览

简要总结

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

研究设计

研究类型
Observational
观察模型
Ecologic Or Community
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Willing and able to provide written informed consent
  • At least 18 years of age
  • Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
  • Initiating panobinostat within 60 days of enrollment
  • ECOG performance status 0-1
  • Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
  • Willing and able to complete the PRO questionnaire

排除标准

  • Diagnosed with any B-cell malignancy other than myeloma
  • Estimated life expectancy <6 months
  • Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)

结局指标

主要结局

Response to treatment

时间窗: 24 months

Looking for patient reproted response to treatment with panobinostat

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验